Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{190940,
        author = {Mrunali Gaikwad and Rajeshwari khairnar and Dr Rupali Tasgaonkar},
        title = {Assessing the risk of the brain tumor in young population},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {12},
        number = {8},
        pages = {5124-5131},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=190940},
        abstract = {Brain tumors in the young population represent a significant and evolving public health concern becauseof their biological heterogeneity, rising incidence, and long-term impact on survival and quality of life. This review provides a comprehensive overview of the epidemiology, risk factors, tumor classification, diagnostic approaches, and therapeutic strategies for brain and central nervous system (CNS) tumors affecting children, adolescents, and young adults. Global epidemiological trends indicate a steady increase in CNS tumor incidence, with notable regional variations influenced by socioeconomic development and healthcare access. Genetic alterations, including distinct molecular and epigenetic signatures, play a pivotal role in tumor initiation and progression, whereas environmental exposures, particularly ionizing radiation and pollutants, remain important modifiable risk factors. Advances in neuroimaging, molecular diagnostics, and histopathological classification have improved early detection and tumor stratification in recent years. Current treatment modalities, including surgery, radiotherapy, and chemotherapy, remain central to management; however, therapeutic resistance and treatment-related morbidity continue to pose challenges. Emerging approaches, such as nanotechnology-based drug delivery systems, offer promising avenues for enhancing blood–brain barrier penetration and improving therapeutic efficacy. Despite these advances, limitations in data capture and variability in exposure assessment highlight the need for prospective studies and standardized methodologies. Overall, this review underscores the importance of integrated molecular research, early diagnosis, and innovative treatment strategies for improving outcomes in young patients with brain tumors.},
        keywords = {Brain tumors; Central nervous system neoplasms; Young population; Epidemiology; Risk factors; Molecular profiling; Neuroimaging; Treatment strategies; Nanotechnology; Prognosis},
        month = {January},
        }